Condition
LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) clinical trials that are recruiting, at sites in 3 countries (most in Italy (3), United States (1), Spain (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Engineered HMGB1 protein as a companion therapy for LAMA2-related muscular dystrophy | — | Milan | Recruiting | Aug 4, 2026 |
| Natural history and biomarker mapping for LAMA2-related dystrophy | — | Milan | Recruiting | Aug 15, 2025 |
| Natural history and biomarker mapping for LAMA2-related dystrophy | — | Milan | Recruiting | Aug 15, 2025 |
| Natural history study of LAMA2 muscular dystrophy in children | — | Barcelona, Barcelona | Recruiting | Apr 11, 2025 |
| Tracking movement and health in children 0–5 with LAMA2-related congenital muscular dystrophy | — | Los Angeles, California and 13 other locations | Recruiting | Jul 16, 2024 |
All recruiting trials (5)
-
Engineered HMGB1 protein as a companion therapy for LAMA2-related muscular dystrophy
This study tests how existing patient samples from people with LAMA2-related muscular dystrophy can be used to explore a potential companion therapy using an engineered HMGB1 protein.
-
Natural history and biomarker mapping for LAMA2-related dystrophy
It will track how LAMA2-related dystrophy changes over time in children and adults and look for biological markers that match disease features.
-
Natural history and biomarker mapping for LAMA2-related dystrophy
It will track how LAMA2-related dystrophy changes over time in children and adults and look for biological markers that match disease features.
-
Natural history study of LAMA2 muscular dystrophy in children
This study is trying to understand how LAMA2 muscular dystrophy affects children over time to help improve future treatments.
-
Tracking movement and health in children 0–5 with LAMA2-related congenital muscular dystrophy
This project will see how children aged 0–5 with LAMA2-related dystrophy move, breathe, and develop over two years to help find reliable outcome measures for future treatments.
Related topics
Quick answers
How many LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in Italy (3 trials), United States (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.